SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10646	Companies
226482	Keywords
154956	Articles
119883	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/23/2025 at 07:00, 1 year ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally

Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
PRESS RELEASE

published on 06/23/2025 at 07:00, 1 year ago

Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple. Recommandation basée sur l'étude de phase 3 GMMG-HD7 montrant amélioration significative de la SSP

Myélome Multiple Approbation Sarclisa CHMP GMMG-HD7
BRIEF

published on 06/20/2025 at 07:05, 1 year ago

FDA Approves Dupixent for Bullous Pemphigoid Treatment

FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease
BRIEF

published on 06/20/2025 at 07:05, 1 year ago

La FDA approuve le Dupixent pour le traitement de la pemphigoïde bulleuse

Approbation De La FDA Dupixent Pemphigoïde Bulleuse Inflammation De Type 2 Maladie Cutanée Rare
PRESS RELEASE

published on 06/20/2025 at 07:00, 1 year ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine for bullous pemphigoid, meeting the critical treatment needs of patients with uncontrolled disease

FDA Approval Chronic Disease Dupixent Type 2 Inflammation Bullous Pemphigoid
PRESS RELEASE

published on 06/20/2025 at 07:00, 1 year ago

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse
Dupixent approuvé par la FDA aux États-Unis pour traiter la pemphigoïde bulleuse, offrant une nouvelle approche ciblée contre l'inflammation de type 2. Résultats positifs de l'étude ADEPT

FDA Dupixent Pemphigoïde Bulleuse Inflammation De Type 2 Étude ADEPT
BRIEF

published on 06/17/2025 at 13:45, 1 year ago

Sanofi Successfully Prices €1.5 Billion Bond Issue

Bond Issue Corporate Financing Sanofi Fixed-rate Notes Euro Medium Term Note
BRIEF

published on 06/17/2025 at 13:45, 1 year ago

Sanofi fixe avec succès le prix d'une émission obligataire de 1,5 milliard d'euros

Emission D'obligations Sanofi Financement Des Entreprises Obligations À Taux Fixe Billet À Moyen Terme En Euros
PRESS RELEASE

published on 06/17/2025 at 13:40, 1 year ago

Press release: Sanofi successfully prices €1.5 billion bond issue
Sanofi successfully prices €1.5 billion bond issue with fixed-rate notes across 2 tranches, using proceeds for general corporate purposes, led by Citigroup and RBC Capital Markets, under Euro Medium Term Note Programme

Financial Markets Bond Issue Sanofi Euro Medium Term Note Programme Fixed-rate Notes
PRESS RELEASE

published on 06/17/2025 at 13:40, 1 year ago

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires
Sanofi place 1,5 milliard d’euros d’emprunts obligataires avec succès pour financer ses besoins généraux. Citigroup et RBC Capital Markets ont agi en tant que coordinateurs

Sanofi Citigroup RBC Capital Markets Emprunts Obligataires Besoins Généraux

Accesswire

Published on 06/26/2026 at 15:05, 1 hour 56 minutes ago

Vox Royalty Sells I-80 Gold Offtake Stream
Published on 06/26/2026 at 14:05, 2 hours 56 minutes ago

SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 3 hours 1 minute ago

Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 4 hours 1 minute ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 4 hours 16 minutes ago

Northern Dynasty Reports Oral Arguments Held

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 16:38, 23 minutes ago

Cairn Homes Plc: Notice of H1 2026 Trading Update
Published on 06/26/2026 at 15:30, 1 hour 31 minutes ago

JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 37 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour 38 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 39 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Senior plc

Les Echos

Published on 06/26/2026 at 14:44, 2 hours 17 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 2 hours 17 minutes ago

Information Safran
Published on 06/26/2026 at 12:16, 4 hours 45 minutes ago

Rapport semestriel SIEHM au 30 avril 2026
Published on 06/26/2026 at 07:00, 10 hours 1 minute ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 10 hours 1 minute ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel

View all LES ECHOS COMFI WIRE